Get a high resolution logo for any domain or stock ticker — for free

AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing products for the treatment and management of various cancers. Its primary product candidate is StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. The company was founded in 2013 and is headquartered in New York, New York.